![Andrew Maleki](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andrew Maleki
Finansdirektör/CFO på
SURROZEN, INC.
Förmögenhet: 19 533 $ per 2026-09-30
Profil
Andrew Maleki is Chief Financial Officer at Surrozen, Inc. since 2025.
Mr. Maleki was Head-Corporate Development at Lassen Therapeutics, Inc. from 2021 to 2025.
Mr. Maleki completed undergraduate studies at Yale University and earned an MBA from Harvard Business School.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
SURROZEN INC 0,01 % | 2026-06-15 | 607 ( 0,01 % ) | 19 533 $ | 2026-09-30 |
Aktiva positioner av Andrew Maleki
| Företag | Position | Start |
|---|---|---|
| SURROZEN, INC. | Finansdirektör/CFO | 2025-11-12 |
Tidigare kända positioner av Andrew Maleki
| Företag | Position | Slut |
|---|---|---|
Lassen Therapeutics 1, Inc.
 Lassen Therapeutics 1, Inc. BiotechnologyHealth Technology Develops novel and best-in-class biotherapeutics | Företagsledare/Principal | 2025-10-01 |
Andrew Malekis utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
15
Första gradens relationer
4
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lassen Therapeutics 1, Inc.
Lassen Therapeutics 1, Inc. BiotechnologyHealth Technology Develops novel and best-in-class biotherapeutics | Health Technology |
Surrozen, Inc.
 Surrozen, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovering and developing drug candidates | Health Technology |
